In a double-blind crossover trial, 8 weeks of pharmaceutical CBD (Epidiolex) altered brain wave patterns and improved visual-motor and non-verbal cognitive abilities in boys with autism requiring higher support—and blood CBD metabolite levels predicted the brain changes.
Families of children with ASD, pediatric neurologists, autism researchers, and clinicians exploring CBD for neurodevelopmental conditions.
What the researchers found
This study analyzed EEG data from 24 boys with autism spectrum disorder (ASD) and higher support needs, drawn from a Phase II clinical trial of pharmaceutical-grade CBD (Epidiolex, up to 20 mg/kg/day).
The EEG analysis went beyond traditional approaches, examining both periodic (oscillatory) and aperiodic components of brain activity. After 8 weeks of CBD treatment, specific aperiodic EEG measures changed in ways that correlated with CBD metabolite levels in blood—providing a direct biological link between drug exposure and brain function.
The most striking finding: CBD metabolite levels were associated with improvements in visuomotor abilities and non-verbal cognitive skills. These are core deficit areas for children with ASD requiring higher levels of support, and there are few effective treatments for them.
The brain wave changes included a larger aperiodic offset across the scalp and a decreased aperiodic exponent—technical measures that reflect the overall excitation-inhibition balance of the brain. Given RTHC-00217's finding that cannabinoids affect the GABA excitation-inhibition balance, this EEG finding may reflect CBD modulating the same fundamental neural property in a therapeutic direction for ASD.
This is the first study to use FDA-approved purified CBD in children with ASD and higher support needs, and the first to link CBD blood levels directly to EEG biomarkers and cognitive outcomes in this population.
Why it matters
Children with ASD requiring higher levels of support have very few treatment options for core cognitive deficits. Current medications primarily address behavioral symptoms (irritability, aggression) rather than cognitive abilities. If CBD can improve visuomotor and non-verbal cognition—and this improvement is measurable via EEG biomarkers—it could represent a genuinely new therapeutic approach for the most affected children.
The numbers in context
N = 24 boys, ages 7–14. Higher support needs ASD. 8 weeks CBD (Epidiolex, up to 20 mg/kg/day). Double-blind crossover. Aperiodic EEG changes correlated with CBD metabolite levels. Improvements in visuomotor and non-verbal cognitive abilities.
How the study worked
Analysis of EEG data from 24 boys with ASD and higher support needs (ages 7–14) from a double-blind, placebo-controlled, crossover Phase II trial (NCT04517799). 8 weeks of daily CBD (up to 20 mg/kg/day Epidiolex). EEG at baseline, post-CBD, post-placebo, and post-washout. Linear mixed-effects models linking aperiodic EEG measures with CBD metabolite blood levels and cognitive outcomes.
Who was studied
N=24 boys aged 7-14 years with autism spectrum disorder requiring higher support, participating in a clinical trial.
What this study cannot tell us
Small sample (24 boys). Only boys—ASD presents differently in girls and CBD effects may differ. The cognitive improvements were associated with CBD metabolite levels, not with treatment condition per se, suggesting individual pharmacokinetic variability matters. Crossover design means each child received both CBD and placebo, but period effects are possible. 8 weeks may not be long enough to assess sustained cognitive changes. Higher-support-needs ASD is heterogeneous.
How to read the evidence
Double-blind, placebo-controlled, crossover Phase II trial with EEG biomarkers and blood-level correlations—rigorous design, though small sample.
When this study was published
Published in 2026 in Translational Psychiatry, representing a new frontier for CBD therapeutics.
The bigger picture
This represents an entirely new therapeutic direction for CBD—beyond epilepsy (RTHC-00189, 00186, 00165) and pain (RTHC-00225) into neurodevelopmental conditions. The EEG biomarker approach connects to the broader effort to develop objective measures of cannabis/CBD effects (see RTHC-00221's UPE biomarker for anxiety). And the use of FDA-approved Epidiolex rather than unregulated CBD products means the results are clinically actionable.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Would the cognitive benefits persist with longer treatment? Do girls with ASD show the same response? Could EEG biomarkers predict which children will respond to CBD before starting treatment? What is the optimal CBD dose for ASD—is 20 mg/kg/day the ceiling?
Read the original research
Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support.
Translational psychiatry, 16(1)
Translational Psychiatry is a reputable journal focusing on the intersection of psychiatry and neuroscience.
Citation
Cazares, Christian; Hutton, Austin; Paez, Gisselle; Trauner, Doris; Voytek, Bradley. (2026). Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support.. Translational psychiatry, 16(1). https://doi.org/10.1038/s41398-026-03815-y
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- Why Does Weed Make You Emotional? THC and Emotional Processing
- THC and Productivity: Does Weed Help or Hurt Your Output
- THC and Studying: What the Research Says About Cannabis and Learning